Xiping Zhang, Bo Chen, Shifeng Yang, Feijiang Yu, Hongjian Yang, Qihui Cheng, Binbin Tang
Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
Department of Pathology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China.
Oncotarget. 2017 Dec 18;9(2):2255-2267. doi: 10.18632/oncotarget.23370. eCollection 2018 Jan 5.
As a type of new targets for prognosis of malignancies, long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcription 1) is associated with proliferation and metastatic abilities of several malignancies. However, its relations to development and migration of triple negative and human epidermal growth factor receptor 2 (Her-2) positive breast cancers haven't been reported.
In this paper, we aimed to discuss how MALAT1 is connected with and affects proliferation and invasion abilities of cells in Her-2 positive and triple-negative breast cancers (TNBC).
The expression of MALAT1 in clinical samples with TNBC and Her-2 positive breast cancers was tested by qRT-PCR. The statistical analysis was performed to unveil the potential relationships between the expression of MALAT1 and prognostic factors of breast cancer such as OS (overall survival), RFS (relapse-free survival), number of metastatic lymph nodes and pTNM staging in patients with TNBC or Her-2 positive breast cancer. MALAT1 and XBP1 were knockdown respectively in Her-2 positive cell line MDA-MB-231, and MALAT1 and Her-2 were knockdown respectively in TNBC cell line MDA-MD-435 using siRNA. The alterations of expressions of MALAT1 and related genes were detected by qRT-PCR in two breast cancer cell lines. The changes of proliferation abilities in two cell lines were observed using CCK8 assays. Furthermore, transwell assays were performed to detect changes to invasion abilities of the cells.
The expression of MALAT1 in triple negative and Her-2 positive breast cancers was positively correlated to the number of metastatic lymph nodes in patients with breast cancer. MALAT1 promotes proliferation and invasion abilities of breast cancer cells through XBP1 (X-box binding protein 1)-HIF (hypoxia-inducible factor)-1α pathway in MDA-MB-231 and through Her-2 pathway in MDA-MD-435. Moreover, MALAT1 could possibly be involved in regulation of MYC gene and CD47 (an immune checkpoint gene) in both cell lines.
Our study suggested that MALAT1 is a core signaling molecule for promoting development and migration of triple negative and Her-2 positive breast cancers. It would be employed as common markers for prognosis of the two types of breast cancer mentioned above and potential targets for treating them.
作为恶性肿瘤预后的一类新靶点,长链非编码RNA MALAT1(转移相关的肺腺癌转录本1)与多种恶性肿瘤的增殖和转移能力相关。然而,其与三阴性及人表皮生长因子受体2(Her-2)阳性乳腺癌发生发展及迁移的关系尚未见报道。
本文旨在探讨MALAT1如何与Her-2阳性及三阴性乳腺癌(TNBC)细胞的增殖和侵袭能力相关联并产生影响。
采用qRT-PCR检测MALAT1在TNBC及Her-2阳性乳腺癌临床样本中的表达。进行统计分析以揭示MALAT1表达与TNBC或Her-2阳性乳腺癌患者的乳腺癌预后因素如总生存期(OS)、无复发生存期(RFS)、转移淋巴结数量及pTNM分期之间的潜在关系。使用小干扰RNA(siRNA)分别在Her-2阳性细胞系MDA-MB-231中敲低MALAT1和XBP1(X盒结合蛋白1),并在TNBC细胞系MDA-MD-435中分别敲低MALAT1和Her-2。通过qRT-PCR检测两种乳腺癌细胞系中MALAT1及相关基因表达的变化。使用CCK8法观察两种细胞系增殖能力的变化。此外,进行Transwell实验以检测细胞侵袭能力的变化。
MALAT1在三阴性和Her-2阳性乳腺癌中的表达与乳腺癌患者的转移淋巴结数量呈正相关。MALAT1在MDA-MB-231中通过XBP1-HIF(缺氧诱导因子)-1α途径,在MDA-MD-435中通过Her-2途径促进乳腺癌细胞的增殖和侵袭能力。此外,MALAT1可能在两种细胞系中均参与MYC基因和CD47(一种免疫检查点基因)的调控。
我们的研究表明,MALAT1是促进三阴性和Her-2阳性乳腺癌发生发展及迁移的核心信号分子。它可作为上述两种类型乳腺癌预后的共同标志物及治疗的潜在靶点。